The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®-Reference-Cited by-同舟云学术

The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®

Published:2016-09-20 Issue:7 Volume:8 Page:1417-1424
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Ganguly Bishu¹,Balasa Balaji¹,Efros Lyubov¹,Hinton Paul R.²,Hartman Stephen³,Thakur Archana²,Xiong Joanna M.²,Schmidt Brian³,Robinson Randy R.⁴,Sornasse Thierry¹,Vexler Vladimir¹,Sheridan James P.¹

Affiliation:

1. Department Translational Medicine, AbbVie Biotherapeutics, Redwood City, CA, USA

2. Department Discovery Sciences, AbbVie Biotherapeutics, Redwood City, CA, USA

3. Department Analytical Development & QC, AbbVie Biotherapeutics, Redwood City, CA, USA

4. Department of Neuroscience Development, AbbVie Biotherapeutics, Redwood City, CA, USA

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://tandfonline.com/doi/pdf/10.1080/19420862.2016.1207031

Reference28 articles.